Structure Therapeutics (NASDAQ: GPCR) — Perfil da empresa, notícias e dados financeiros
Structure Therapeutics designs novel therapies for chronic metabolic diseases, leveraging structural biology to address unmet needs.
Structure Therapeutics
Structure Therapeutics (NASDAQ:GPCR) is a biopharmaceutical company focused on designing and developing novel therapies aimed at treating chronic metabolic diseases. At the heart of their operations is a platform technology that leverages structural biology to discover and optimize therapeutics that can modulate G protein-coupled receptors (GPCRs), a large family of proteins that play a crucial role in various physiological processes. Their projects primarily focus on addressing unmet needs in obesity, diabetes, and other metabolic disorders, aiming to bring forth innovative treatment options for patients worldwide. Structure Therapeutics is committed to pushing the boundaries of drug discovery, aiming to enhance patient health and quality of life through their scientific and clinical advancements.
Resumo
Operações
Produtos e/ou serviços de Structure Therapeutics
- Development of oral small molecule GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity, targeting a core need in metabolic disorder treatments.
- Advancement of oral small molecule CGRP receptor antagonists, aimed at preventing migraine, addressing the growing need for effective migraine management solutions.
- Proprietary platform for structure-based drug discovery, enabling the rapid and efficient identification of novel therapeutics targeting G protein-coupled receptors (GPCRs).
- Research into oral small molecule GIP receptor agonists, exploring their potential in improving outcomes for patients with metabolic diseases.
- Development of dual agonists targeting both GLP-1 and GIP receptors, seeking to offer superior treatment options for diabetes and obesity.
- Custom drug discovery services, leveraging their structural biology expertise to aid in the development of GPCR-targeting drugs for external partners.
equipe executiva do Structure Therapeutics
- Raymond C. StevensCEO & Director
- Jun S. YoonCo- Founder, CFO & Secretary
- Yingli MaChief Technology Officer
- Xichen LinChief Scientific Officer & GM of Structure Shanghai
- Blai CollChief Medical Officer
- Matthew LangCOO & General Counsel
- Bob GatmaitanSenior Vice President of People
- Hui LeiSenior Vice President of Chemistry
- Fang ZhangExecutive VP & Head of Biology
- Lani IbarraSenior Vice President of Clinical Development Operations
Principais indicadores financeiros
Resultados divulgados pela Structure Therapeutics , em USD.
- Cap. de mercado
- 1,5 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -3.0
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -287,6 mi | -141,2 mi | |
| 0 | -158,2 mi | -122,5 mi | |
| 0 | -102,8 mi | -89,6 mi | |
| 0 | -52,6 mi | -51,3 mi |